Search tips
Search criteria 


Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
AAPS PharmSciTech. 2007 March; 8(1): E13–E20.
Published online 2007 January 19. doi:  10.1208/pt0801002
PMCID: PMC2750430

Transdermal therapeutic system of carvedilol: Effect of hydrophilic and hydrophobic matrix on in vitro and in vivo characteristics


The purpose of this research was to develop a matrix-type transdermal therapeutic system containing carvedilol with different ratios of hydrophilic and hydrophobic polymeric combinations by the solvent evaporation technique. The physicochemical compatibility of the drug and the polymers was studied by infrared spectroscopy and differential scanning calorimetry. The results suggested no physicochemical incompatibility between the drug and the polymers. In vitro permeation studies were performed by using Franz diffusion cells. The results followed Higuchi kinetics (r=0.9953−0.9979), and the mechanism of release was diffusion mediated. Based on physicochemical and in vitro skin permeation studies, patches coded as F3 (ethyl cellulose: polyvinylpyr-rolidone, 7.5[ratio]2.5) and F6 (Eudragit RL:Eudragit RS, 8[ratio]2) were chosen for further in vivo studies. The bioavailability studies in rats indicated that the carvedilol transdermal patches provided steady-state plasma concentrations with minimal fluctuations and improved bioavailability of 71% (for F3) and 62% (for F6) in comparison with oral administration. The antihypertensive activity of the patches in comparison with that of oral carvedilol was studied using methyl prednisolone acetate—induced hypertensive rats. It was observed that both the patches significantly controlled hypertension from the first hour (P<.05). The developed transdermal patches increase the efficacy of carvedilol for the therapy of hypertension.

Full Text

The Full Text of this article is available as a PDF (249K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Mollendorff EV, Reiff K, Neugebauer G. Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker. Eur J Clinical Pharm. 1987;33:511–513. doi: 10.1007/BF00544245. [PubMed] [Cross Ref]
2. Dollery C. Therapeutics Drugs. Edinburgh, UK: Churchill Livingstone; 1999. pp. 75–80.
3. Chien YW. Transdermal therapeutic system. In: Robinson JR, Lee VHL, editors. Controlled Drug Delivery Fundamentals and Applications. 2nd ed. New York, NY: Marcel Dekker; 1987. pp. 524–552.
4. Keith AD. Polymer matrix consideration for transdermal devices. Drug Dev Ind Pharm. 1983;9:605–621. doi: 10.3109/03639048309044695. [Cross Ref]
5. Thassu D, Vyas SP. Controlled transdermal mucolytic delivery system. Drug Dev Ind Pharm. 1991;17:561–576. doi: 10.3109/03639049109044263. [Cross Ref]
6. Wade A, Weller PJ. Handbook of Pharmaceutical Excipients. Washington, DC: American Pharmaceutical Publishing Association; 1994. pp. 362–366.
7. Panigrahi L, Pattnaik S, Ghosal SK. The effect of pH and organic ester penetration enhancers on skin permeation kinetics of terbutaline sulfate from pseudolatex-type transdermal delivery systems through mouse and human cadaver skins. AAPS PharmSciTech. 2005;6:E167–E173. doi: 10.1208/pt060225. [PMC free article] [PubMed] [Cross Ref]
8. Arora P, Mukherjee P. Design, development, physicochemical, and in vitro and in vivo evaluation of transdermal patches containing diclofenac diethylammonium salt. J Pharm Sci. 2002;91:2076–2089. doi: 10.1002/jps.10200. [PubMed] [Cross Ref]
9. Gupta R, Mukherjee B. Development and in vitro evaluation of diltiazem hydrochloride transdermal patches based on povidone-ethyl cellulose matrices. Drug Dev Ind Pharm. 2003;29:1–7. doi: 10.1081/DDC-120016678. [PubMed] [Cross Ref]
10. Gehr TWB, Tenero DM, Boyle DA, Qian Y, Sica DA, Shusterman NH. The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. Eur J Clin Pharmacol. 1999;55:299–277. doi: 10.1007/s002280050628. [PubMed] [Cross Ref]
11. Aqil M, Ali A, Sultana Y, Dubey K, Najmi KA, Pillai KK. In vivo characterization of monolithic matrix type transdermal drug delivery systems of pinacidil monohydrate: a technical note. AAPS PharmSciTech. 2006;7:E1–E1. doi: 10.1208/pt070106. [PMC free article] [PubMed] [Cross Ref]
12. Aqil M, Sultana Y, Ali A, Dubey K, Najmi KA, Pillai KK. Transdermal drug delivery system of a beta blocker: design, in vitro, and in vivo characterization. Drug Deliv. 2004;11:27–31. doi: 10.1080/10717540490265225. [PubMed] [Cross Ref]
13. Namdeo A, Jain NK. Liquid crystalline pharmacogel based enhanced transdermal delivery of propranolol hydrochloride. J Control Release. 2002;82:223–236. doi: 10.1016/S0168-3659(02)00106-2. [PubMed] [Cross Ref]
14. Mutalik S, Udupa N. Glibenclamide transdermal patches: physicochemical, pharmacodynamic, and pharmacokinetic evaluations. J Pharm Sci. 2004;93:1577–1594. doi: 10.1002/jps.20058. [PubMed] [Cross Ref]
15. Katayose S, Kataoka K. Water-soluble polyion complex associates of DNA and poly(ethylene glycol)-poly(L-lysine) block copolymer. Bioconjug Chem. 1997;8:702–707. doi: 10.1021/bc9701306. [PubMed] [Cross Ref]
16. Ritger PL, Peppas NA. A simple equation for description of solute release, I: Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs. J Control Release. 1987;5:23–26. doi: 10.1016/0168-3659(87)90034-4. [Cross Ref]
17. Rao PR, Diwan PV. Formulation and in vitro evaluation of polymeric films of diltiazem hydrochloride and indomethacin for transdermal administration. Drug Dev Ind Pharm. 1998;24:327–336. doi: 10.3109/03639049809085627. [PubMed] [Cross Ref]
18. Draize JH, Woodward G, Calvery HO. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther. 1944;82:377–379.

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists